August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 18, 2025

FDA Approves New Indication for Wegovy

Accelerated approval granted to Wegovy for treatment of noncirrhotic metabolic dysfunction–associated steatohepatitis in adults with stage F2 to F3 fibrosis.

Conexiant

August 11, 2025

FDA OKs Bioequivalent Iron Sucrose for CKD Anemia

The FDA has approved a bioequivalent iron sucrose injection for treating iron deficiency anemia in patients with chronic kidney disease.

Conexiant

August 01, 2025

Physicians Urged to Defend USPSTF Role

The Colorectal Cancer Alliance and partners are urging the Department of Health and Human Services to preserve U.S. Preventive Services Task Force’s evidence-based role in safeguarding access to no-cost colorectal cancer screening.

Conexiant

April 26, 2024

FDA Grants Orphan Drug Designation to Novel Pancreatic Cancer Drug Candidate

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the novel drug candidate FL118 for the treatment of patients with pancreatic cancer.

Conexiant

April 26, 2024

Irinotecan Liposome Approved by FDA for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.

Conexiant

October 18, 2024

FDA Approves New Gastric Cancer Therapy

The FDA has approved Vyloy, a monoclonal antibody, for the treatment of gastric cancer in combination with chemotherapy, marking a significant step in targeted therapy for this disease.

Reuters

November 22, 2024

FDA Official Expects Tightened Vaccine Review

"I don't necessarily view that as a bad thing."

Reuters